Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ranibizumab · 1 trial · 2 indications
Mean change in ETDRS letter score from baseline
| Arm | Type | Description |
|---|---|---|
| Squalamine and ranibizumab to Week 10 | EXPERIMENTAL | All eyes received an initial 10 week mandatory loading period of topical Squalamine Lactate Ophthalmic Solution, 0.2% therapy. All eyes received mandatory intravitreal injections of ranibizumab 0.5mg at the conclusions of weeks 2 and 6. Randomize at Week 10 to 2 different groups - Squalamine and No Squalamine, continue PRN ranibizumab in both groups |
| Continue Squalamine, ranibizumab PRN | EXPERIMENTAL | Continue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN |
| Stop Squalamine, ranibizumab PRN | EXPERIMENTAL | Discontinue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN |
| Name | Type | Description |
|---|---|---|
| ranibizumab | DRUG | 0.5 mg IVT ranibizumab |
| Squalamine Lactate Ophthalmic Solution, 0.2% | DRUG | Squalamine Lactate Ophthalmic Solution BID |
Inclusion Criteria: * Eyes with treatment naïve, center involving macular edema secondary to BRVO, HRVO or CRVO in patients of at least 40 years of age * Macular edema of 1-4 months duration prior to the baseline visit * Best corrected baseline ETDRS visual acuity of 20/40 to 20/320 Snellen equival...
Ranibizumab is a small molecule being studied for the treatment of Retinal Vein Occlusion, specifically for macular edema related to this condition. It is currently in Phase 1 clinical development and is not yet approved for this use.
Ranibizumab is being developed by Cumberland Pharmaceuticals Inc., a company traded on the NASDAQ under the ticker symbol CPIX. The drug is currently in Phase 1 clinical trials for Retinal Vein Occlusion.
Ranibizumab is in Phase 1 clinical development for Retinal Vein Occlusion. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
Ranibizumab has one completed clinical trial, NCT02614937, titled 'Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion'. This Phase 1 trial enrolled 20 participants with Retinal Vein Occlusion and Macular Edema.
Ranibizumab is the drug name used in the context of this development program, and the clinical trial NCT02614937 refers to the study of Squalamine Lactate. The trial is investigating ranibizumab for macular edema related to Retinal Vein Occlusion.